Immune landscape and oncobiota in HPV-Associated Colorectal Cancer: an explorative study.
Bacteroides
Colorectal cancer
Human Papillomavirus
Immune evasion
Immunity
Microbiota
Oncobiota
Journal
Clinical and experimental medicine
ISSN: 1591-9528
Titre abrégé: Clin Exp Med
Pays: Italy
ID NLM: 100973405
Informations de publication
Date de publication:
23 Aug 2023
23 Aug 2023
Historique:
received:
21
07
2023
accepted:
07
08
2023
medline:
24
8
2023
pubmed:
24
8
2023
entrez:
23
8
2023
Statut:
aheadofprint
Résumé
Worldwide more than 550,000 new patients suffering from malignant tumors are associated with human papillomaviruses (HPV) infection. However, only a small portion of patients infected progress to cancer, suggesting that other factors other than HPV may play a role. Some studies have investigated HPV infection in colorectal cancer (CRC) with discordant results; moreover, the role of HPV in CRC development is still unknown. We investigated HPV infection in 50 CRC from different regions, excluding the anal one, by immunohistochemistry (IHC), real-time PCR and RNA-seq. For each patient, we studied the tumor microenvironment in neoplastic and matched non-neoplastic samples, and we compared the tumor-infiltrating immune cell phenotypes among HPV-positive and negative samples. Finally, we compared the CRC-associated microbiota in HPV-positive and negative neoplastic samples by 16S rRNA sequencing. HPV infection was identified in 20% of CRC from the right side (caecum, ascending and transverse colon) and in 40% from the left side (descending colon and rectum). In all HPV-positive CRCs we found no expression of p53 and RB, thus suggesting HPV involvement in tumorigenesis. As far as the tumor microenvironment is concerned, in HPV-related cancers we observed a neoplastic environment with a reduced immune surveillance but an enhanced cytotoxic response by lymphocytes. HPV-positive and -negative CRC showed a different microbiota with lack of species normally found in CRC in the HPV-positive ones. Our results support the carcinogenic significance of HPV in CRC, suggesting a role of HPV in modulating the tumor immune microenvironment.
Identifiants
pubmed: 37612430
doi: 10.1007/s10238-023-01165-3
pii: 10.1007/s10238-023-01165-3
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2023. The Author(s).
Références
Ambrosio MR, Vernillo R, De Carolis S, et al. Putative role of circulating human papillomavirus DNA in the development of primary squamous cell carcinoma of the middle rectum: a case report. Front Oncol. 2019;9:93. https://doi.org/10.3389/fonc.2019.00093 .
doi: 10.3389/fonc.2019.00093
pubmed: 30847303
pmcid: 6394246
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer J Clin. 2021;71:209–49. https://doi.org/10.3322/caac.21660 .
doi: 10.3322/caac.21660
Shamseddine AA, Burman B, Lee NY, Zamarin D, Riaz N. Tumor immunity and immunotherapy for HPV-related cancers. Cancer Discov. 2021;11:1896–912. https://doi.org/10.1158/2159-8290.Cd-20-1760 .
doi: 10.1158/2159-8290.Cd-20-1760
pubmed: 33990345
pmcid: 8338882
Mishra GA, Pimple SA, Shastri SS. An overview of prevention and early detection of cervical cancers. Indian J Med Paediatr Oncol: Offic J Indian Soc Med Paediatr Oncol. 2011;32:125–32. https://doi.org/10.4103/0971-5851.92808 .
doi: 10.4103/0971-5851.92808
Stern PL. Harnessing immunity for therapy in human papillomavirus driven cancers. Tumour Virus Res. 2021;11:200212. https://doi.org/10.1016/j.tvr.2021.200212 .
doi: 10.1016/j.tvr.2021.200212
pubmed: 33602657
pmcid: 7942755
Roden RBS, Stern PL. Opportunities and challenges for human papillomavirus vaccination in cancer. Nat Rev Cancer. 2018;18:240–54. https://doi.org/10.1038/nrc.2018.13 .
doi: 10.1038/nrc.2018.13
pubmed: 29497146
pmcid: 6454884
Ambrosio MR, Onorati M, Rocca BJ, Santopietro R. Vulvar cancer and HPV infection: analysis of 22 cases. Pathologica. 2008;100:405–7.
pubmed: 19253600
Smola S, Trimble C, Stern PL. Human papillomavirus-driven immune deviation: challenge and novel opportunity for immunotherapy. Therapeut Adv Vaccin. 2017;5:69–82. https://doi.org/10.1177/2051013617717914 .
doi: 10.1177/2051013617717914
Litwin TR, Clarke MA, Dean M, Wentzensen N (2017) Somatic host cell alterations in HPV carcinogenesis. Viruses. https://doi.org/10.3390/v9080206
Zhou C, Tuong ZK, Frazer IH. Papillomavirus immune evasion strategies target the infected cell and the local immune system. Front Oncol. 2019;9:682. https://doi.org/10.3389/fonc.2019.00682 .
doi: 10.3389/fonc.2019.00682
pubmed: 31428574
pmcid: 6688195
Lin D, Kouzy R, Abi Jaoude J, Noticewala SS, Delgado Medrano AY, Klopp AH, Taniguchi CM, Colbert LE. Microbiome factors in HPV-driven carcinogenesis and cancers. PLoS Pathog. 2020;16:e1008524. https://doi.org/10.1371/journal.ppat.1008524 .
doi: 10.1371/journal.ppat.1008524
pubmed: 32497113
pmcid: 7271998
Santella B, Schettino MT, Franci G, De Franciscis P, Colacurci N, Schiattarella A, Galdiero M. Microbiota and HPV: the role of viral infection on vaginal microbiota. J Med Virol. 2022;94:4478–84. https://doi.org/10.1002/jmv.27837 .
doi: 10.1002/jmv.27837
pubmed: 35527233
pmcid: 9544303
Pal A, Kundu R. Human papillomavirus E6 and E7: the cervical cancer hallmarks and targets for therapy. Front Microbiol. 2019;10:3116. https://doi.org/10.3389/fmicb.2019.03116 .
doi: 10.3389/fmicb.2019.03116
pubmed: 32038557
Pelizzer T, Dias CP, Poeta J, Torriani T, Roncada C. Colorectal cancer prevalence linked to human papillomavirus: a systematic review with meta-analysis. Rev Bras Epidemiol = Braz J Epidemiol. 2016;19:791–802. https://doi.org/10.1590/1980-5497201600040009 .
doi: 10.1590/1980-5497201600040009
Vuitton L, Jaillet C, Jacquin E, et al. Human papillomaviruses in colorectal cancers: a case-control study in western patients. Dig Liver Dis: Off J Ital Soc Gastroenterol Ital Assoc Study Liver. 2017;49:446–50. https://doi.org/10.1016/j.dld.2016.11.003 .
doi: 10.1016/j.dld.2016.11.003
Gazzaz F, Mosli MH, Jawa H, Sibiany A. Detection of human papillomavirus infection by molecular tests and its relation to colonic polyps and colorectal cancer. Saudi Med J. 2016;37:256–61. https://doi.org/10.15537/smj.2016.3.13514 .
doi: 10.15537/smj.2016.3.13514
pubmed: 26905346
pmcid: 4800888
Nagtegaal ID, Odze RD, Klimstra D, Paradis V, Rugge M, Schirmacher P, Washington KM, Carneiro F, Cree IA. The 2019 WHO classification of tumours of the digestive system. Histopathology. 2020;76:182–8. https://doi.org/10.1111/his.13975 .
doi: 10.1111/his.13975
pubmed: 31433515
D’Ignazio A, Kabata P, Ambrosio MR, et al. Preoperative oral immunonutrition in gastrointestinal surgical patients: How the tumour microenvironment can be modified. Clin Nutr ESPEN. 2020;38:153–9. https://doi.org/10.1016/j.clnesp.2020.05.012 .
doi: 10.1016/j.clnesp.2020.05.012
pubmed: 32690150
Ghelardi A, Marrai R, Bogani G, Sopracordevole F, Bay P, Tonetti A, Lombardi S, Bertacca G, Joura EA (2021) Surgical treatment of vulvar HSIL: adjuvant HPV Vaccine Reduces Recurrent Disease. Vaccines. 9. https://doi.org/10.3390/vaccines9020083
Westra WH. The pathology of HPV-related head and neck cancer: implications for the diagnostic pathologist. Semin Diagn Pathol. 2015;32:42–53. https://doi.org/10.1053/j.semdp.2015.02.023 .
doi: 10.1053/j.semdp.2015.02.023
pubmed: 25804343
Klaes R, Friedrich T, Spitkovsky D, Ridder R, Rudy W, Petry U, Dallenbach-Hellweg G, Schmidt D, von Knebel DM. Overexpression of p16(INK4A) as a specific marker for dysplastic and neoplastic epithelial cells of the cervix uteri. Int J Cancer. 2001;92:276–84. https://doi.org/10.1002/ijc.1174 .
doi: 10.1002/ijc.1174
pubmed: 11291057
Halec G, Scott ME, Farhat S, Darragh TM, Moscicki AB. Toll-like receptors: Important immune checkpoints in the regression of cervical intra-epithelial neoplasia 2. Int J Cancer. 2018;143:2884–91. https://doi.org/10.1002/ijc.31814 .
doi: 10.1002/ijc.31814
pubmed: 30121951
pmcid: 6419742
Usman M, Hameed Y, Ahmad M. Does human papillomavirus cause human colorectal cancer? Applying Bradford Hill criteria postulates. Ecancermedicalscience. 2020;14:1107. https://doi.org/10.3332/ecancer.2020.1107 .
doi: 10.3332/ecancer.2020.1107
pubmed: 33144875
pmcid: 7581335
Chen H, Chen XZ, Waterboer T, Castro FA, Brenner H. Viral infections and colorectal cancer: a systematic review of epidemiological studies. Int J Cancer. 2015;137:12–24. https://doi.org/10.1002/ijc.29180 .
doi: 10.1002/ijc.29180
pubmed: 25186851
Gornick MC, Castellsague X, Sanchez G, et al. Human papillomavirus is not associated with colorectal cancer in a large international study. Cancer Causes Control : CCC. 2010;21:737–43. https://doi.org/10.1007/s10552-010-9502-0 .
doi: 10.1007/s10552-010-9502-0
pubmed: 20087645
Taherian H, Tafvizi F, Fard ZT, Abdirad A. Lack of association between human papillomavirus infection and colorectal cancer. Przeglad Gastroenterol. 2014;9:280–4. https://doi.org/10.5114/pg.2014.46163 .
doi: 10.5114/pg.2014.46163
Bhatt KH, Neller MA, Srihari S et al. (2020) Profiling HPV-16-specific T cell responses reveals broad antigen reactivities in oropharyngeal cancer patients. J Exp Med. https://doi.org/10.1084/jem.20200389
Miyauchi S, Sanders PD, Guram K, et al. HPV16 E5 mediates resistance to PD-L1 blockade and can be targeted with rimantadine in head and neck cancer. Can Res. 2020;80:732–46. https://doi.org/10.1158/0008-5472.Can-19-1771 .
doi: 10.1158/0008-5472.Can-19-1771
Welters MJP, Ma W, Santegoets S, et al. Intratumoral HPV16-specific T cells constitute a type I-oriented tumor microenvironment to improve survival in hpv16-driven oropharyngeal cancer. Clin Cancer Res: Offic J Am Assoc Cancer Res. 2018;24:634–47. https://doi.org/10.1158/1078-0432.Ccr-17-2140 .
doi: 10.1158/1078-0432.Ccr-17-2140
Santegoets SJ, van Ham VJ, Ehsan I, et al. The anatomical location shapes the immune infiltrate in tumors of same etiology and affects survival. Clin Cancer Res: Offic J Am Assoc Cancer Res. 2019;25:240–52. https://doi.org/10.1158/1078-0432.Ccr-18-1749 .
doi: 10.1158/1078-0432.Ccr-18-1749
Abate F, Ambrosio MR, Mundo L, et al. Distinct viral and mutational spectrum of endemic burkitt lymphoma. PLoS Pathog. 2015;11:e1005158. https://doi.org/10.1371/journal.ppat.1005158 .
doi: 10.1371/journal.ppat.1005158
pubmed: 26468873
pmcid: 4607508
Ryser MD, Myers ER, Durrett R. HPV clearance and the neglected role of stochasticity. PLoS Computat Biol. 2015;11:e1004113. https://doi.org/10.1371/journal.pcbi.1004113 .
doi: 10.1371/journal.pcbi.1004113
Bodelon C, Untereiner ME, Machiela MJ, Vinokurova S, Wentzensen N. Genomic characterization of viral integration sites in HPV-related cancers. Int J Cancer. 2016;139:2001–11. https://doi.org/10.1002/ijc.30243 .
doi: 10.1002/ijc.30243
pubmed: 27343048
pmcid: 6749823
Liu L, Ying C, Zhao Z, et al. Identification of reliable biomarkers of human papillomavirus 16 methylation in cervical lesions based on integration status using high-resolution melting analysis. Clin Epigenet. 2018;10:10. https://doi.org/10.1186/s13148-018-0445-8 .
doi: 10.1186/s13148-018-0445-8
da Mata S, Ferreira J, Nicolás I et al. (2021) P16 and HPV genotype significance in HPV-associated cervical cancer-a large cohort of two tertiary referral centers. Int J Mol Sci. https://doi.org/10.3390/ijms22052294
Goel A, Boland CR. Epigenetics of colorectal cancer. Gastroenterology. 2012;143:1442-60.e1. https://doi.org/10.1053/j.gastro.2012.09.032 .
doi: 10.1053/j.gastro.2012.09.032
pubmed: 23000599
Jee B, Yadav R, Pankaj S, Shahi SK. Immunology of HPV-mediated cervical cancer: current understanding. Int Rev Immunol. 2021;40:359–78. https://doi.org/10.1080/08830185.2020.1811859 .
doi: 10.1080/08830185.2020.1811859
pubmed: 32853049
Niccolai E, Russo E, Baldi S, et al. Significant and conflicting correlation of IL-9 with prevotella and bacteroides in human colorectal cancer. Front Immunol. 2020;11:573158. https://doi.org/10.3389/fimmu.2020.573158 .
doi: 10.3389/fimmu.2020.573158
pubmed: 33488574
Wan J, Wu Y, Huang L, et al. ILC2-derived IL-9 inhibits colorectal cancer progression by activating CD8(+) T cells. Cancer Lett. 2021;502:34–43. https://doi.org/10.1016/j.canlet.2021.01.002 .
doi: 10.1016/j.canlet.2021.01.002
pubmed: 33429004
Wang J, Sun M, Zhao H, et al. IL-9 exerts antitumor effects in colon cancer and transforms the tumor microenvironment in vivo. Technol Cancer Res Treat. 2019;18:1533033819857737. https://doi.org/10.1177/1533033819857737 .
doi: 10.1177/1533033819857737
pubmed: 31242804
pmcid: 6598323
Bing RJ, Miyataka M, Rich KA, Hanson N, Wang X, Slosser HD, Shi SR. Nitric oxide, prostanoids, cyclooxygenase, and angiogenesis in colon and breast cancer. Clin Cancer Res: Offic J Am Assoc Cancer Res. 2001;7:3385–92.
Derosa L, Routy B, Kroemer G, Zitvogel L. The intestinal microbiota determines the clinical efficacy of immune checkpoint blockers targeting PD-1/PD-L1. Oncoimmunology. 2018;7:e1434468. https://doi.org/10.1080/2162402x.2018.1434468 .
doi: 10.1080/2162402x.2018.1434468
pubmed: 29872574
pmcid: 5980343
Kim GW, Lee DH, Jeon YH, Yoo J, Kim SY, Lee SW, Cho HY, Kwon SH (2021) Glutamine synthetase as a therapeutic target for cancer treatment. Int J Mol Sci. https://doi.org/10.3390/ijms22041701
Kodama M, Oshikawa K, Shimizu H, et al. A shift in glutamine nitrogen metabolism contributes to the malignant progression of cancer. Nat Commun. 2020;11:1320. https://doi.org/10.1038/s41467-020-15136-9 .
doi: 10.1038/s41467-020-15136-9
pubmed: 32184390
pmcid: 7078194
Diers AR, Broniowska KA, Chang CF, Hogg N. Pyruvate fuels mitochondrial respiration and proliferation of breast cancer cells: effect of monocarboxylate transporter inhibition. Biochem J. 2012;444:561–71. https://doi.org/10.1042/bj20120294 .
doi: 10.1042/bj20120294
pubmed: 22458763
Keshet R, Szlosarek P, Carracedo A, Erez A. Rewiring urea cycle metabolism in cancer to support anabolism. Nat Rev Cancer. 2018;18:634–45. https://doi.org/10.1038/s41568-018-0054-z .
doi: 10.1038/s41568-018-0054-z
pubmed: 30194362
Mowat AM, Agace WW. Regional specialization within the intestinal immune system. Nat Rev Immunol. 2014;14:667–85. https://doi.org/10.1038/nri3738 .
doi: 10.1038/nri3738
pubmed: 25234148
Flynn KJ, Ruffin MTt, Turgeon DK, Schloss PD,. Spatial variation of the native colon microbiota in healthy adults. Cancer Prevent Res (Philadelphia, PA). 2018;11:393–402. https://doi.org/10.1158/1940-6207.Capr-17-0370 .
doi: 10.1158/1940-6207.Capr-17-0370
Jin M, Shang F, Wu J, et al. Tumor-associated microbiota in proximal and distal colorectal cancer and their relationships with clinical outcomes. Front Microbiol. 2021;12:727937. https://doi.org/10.3389/fmicb.2021.727937 .
doi: 10.3389/fmicb.2021.727937
pubmed: 34650531
pmcid: 8506159
Suga D, Mizutani H, Fukui S, et al. The gut microbiota composition in patients with right- and left-sided colorectal cancer and after curative colectomy, as analyzed by 16S rRNA gene amplicon sequencing. BMC Gastroenterol. 2022;22:313. https://doi.org/10.1186/s12876-022-02382-y .
doi: 10.1186/s12876-022-02382-y
pubmed: 35752764
pmcid: 9233765
Mima K, Cao Y, Chan AT, et al. fusobacterium nucleatum in colorectal carcinoma tissue according to tumor location. Clin Transl Gastroenterol. 2016;7:e200. https://doi.org/10.1038/ctg.2016.53 .
doi: 10.1038/ctg.2016.53
pubmed: 27811909
pmcid: 5543402
Flemer B, Lynch DB, Brown JM, Jeffery IB, Ryan FJ, Claesson MJ, O’Riordain M, Shanahan F, O’Toole PW. Tumour-associated and non-tumour-associated microbiota in colorectal cancer. Gut. 2017;66:633–43. https://doi.org/10.1136/gutjnl-2015-309595 .
doi: 10.1136/gutjnl-2015-309595
pubmed: 26992426